Volume 194, number 12: Immune-Based Therapy for HIV Infection: Are Acute and Chronic HIV Infection Different Diseases?
14th Nov 2006, 01:00 GMT
Volume 194, number 12: Immune-Based Therapy for HIV Infection: Are Acute and Chronic HIV Infection Different Diseases? related news:
- Volume 194, number 12: Cyclosporin A Provides No Sustained Immunologic Benefit to Persons with Chronic HIV-1 Infection Starting Suppressive Antiretroviral Therapy: Results of a Randomized, Controlled Trial of the AIDS Clinical Trials Group A5138 — J Infect Dis Latest Issue
- T for two: Scientists show how immune system chooses best way to fight infection — EurekAlert! - Breaking News
- Volume 194, number 12: Treatment Benefit on Cerebrospinal Fluid HIV-1 Levels in the Setting of Systemic Virological Suppression and Failure — J Infect Dis Latest Issue
- Progress Made In HIV Vaccine Development — ScienceDaily Headlines: Health & Medicine
- Volume 194, number 12: A Randomized, Partially Blinded Phase 2 Trial of Antiretroviral Therapy, HIV-Specific Immunizations, and Interleukin-2 Cycles to Promote Efficient Control of Viral Replication (ACTG A5024) — J Infect Dis Latest Issue
- Chronic Diseases Threaten Economies Across The Globe — Health News from Medical News Today
- Volume 194, number 12: Randomized, Double-Blind, Placebo-Controlled Efficacy Trial of a Bivalent Recombinant Glycoprotein 120 HIV-1 Vaccine among Injection Drug Users in Bangkok, Thailand — J Infect Dis Latest Issue
- Volume 194, number 12: Recurrence of Symptomatic Bacterial Vaginosis 12 Months after Oral Metronidazole Therapy in HIV-Positive and -Negative Women — J Infect Dis Latest Issue
- Radiation Therapy for Chronic Vesicular Hand Dermatitis — Medscape Headlines
- Data on PolyMedix's Novel Antibiotics Presented at the 40th Annual Meeting of the Ocular Microbiology and Immunology Group — Pharmaceuticals News from StratCenter.com
Latest news from J Infect Dis Latest Issue:
- Volume 194, number 12: Phase 1 Safety and Immunogenicity Evaluation of a Multiclade HIV-1 Candidate Vaccine Delivered by a Replication-Defective Recombinant Adenovirus Vector
- Volume 194, number 12: Phase 1 Safety and Immunogenicity Evaluation of a Multiclade HIV-1 DNA Candidate Vaccine
- Volume 194, number 12: Quantification of Viral Inactivation by Photochemical Treatment with Amotosalen and UV A Light, Using a Novel Polymerase Chain Reaction Inhibition Method with Preamplification
- Volume 194, number 12: Cyclosporin A Provides No Sustained Immunologic Benefit to Persons with Chronic HIV-1 Infection Starting Suppressive Antiretroviral Therapy: Results of a Randomized, Controlled Trial of the AIDS Clinical Trials Group A5138
- Volume 194, number 12: Evaluation of Purified Taenia solium Glycoproteins and Recombinant Antigens in the Serologic Detection of Human and Swine Cysticercosis
- Volume 194, number 12: Phase 1 Clinical Trials of the National Institutes of Health Vaccine Research Center HIV/AIDS Candidate Vaccines
- Volume 194, number 12: Is There a Safe Age for Vaccinating Infants with Tetravalent Rhesus-Human Reassortant Rotavirus Vaccine?
- Volume 194, number 12: Reply to Gargiullo et al.
- Volume 194, number 12: Is Panton-Valentine Leukocidin the Major Virulence Determinant in Community-Associated Methicillin-Resistant Staphylococcus aureus Disease?
- Volume 194, number 12: Human Cytolytic T Cell Recognition of Yersinia pestis Virulence Proteins That Target Innate Immune Responses